Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutica...(09 Neptune also amended its stock option...)

Date:5/19/2009

09, Neptune also amended its stock option plan ("Neptune Plan") to provide that each option granted under the Acasti Plan will reduce by one the number of shares available for further issuance under the Neptune Plan and each option cancelled under the Acasti Plan will increase by one, the number of shares available under the Neptune plan, until the date on which the shares of Acasti qualify as "exchange-traded securities" under applicable securities laws and regulations. The Acasti Plan and annual grant of options to purchase Acasti Class A shares must be approved each year by disinterested shareholders of Neptune at its annual general meeting. Accordingly, at the annual general meeting of the shareholders to be held on June 9, 2009, the disinterested shareholders of Neptune will be asked to approve the Acasti Plan and the grant of 850,000 stock options to various Acasti directors, officers and employees made on October 8, 2008. (1) Earnings before Interest, Taxes, Depreciation, and Amortization

About Neptune Technologies & Bioressources Inc.

Neptune is an industry-recognized leader in the innovation, production and formulation of science-based and clinically-proven novel phospholipid products for the nutraceutical and pharmaceutical markets. The Company focuses on growing consumer health markets including cardiovascular, inflammatory and neurological disease driven by consumers taking a more proactive approach to managing health and preventing disease. The Company carries out clinical trials to show the therapeutic benefits in various medical indications and to obtain regulatory approved health claims. Neptune is continuously expanding on its portfolio of intellectual property, clinical studies, regulatory approvals and health claims. Neptune has its products marketed and distributed in over 20 countries worldwide.

About Acasti Pharma

Acasti Pharma is pursuing pharma
'/>"/>

SOURCE NEPTUNE TECHNOLOGIES & BIORESSOURCES INC. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Neptune Product and Distribution Update
2. Neptune Technologies to expect Record Revenues; Fiscal 2009 Third Quarter and Year-End Results
3. Human clinical study demonstrates superior Neptune Krill Oil NKO(R) pharmacokinetic profile
4. Acasti Pharma completes offer to exchange outstanding Neptune Technologies dividend notes
5. Neptune Technologies & Bioressources Inc. reports first quarter results
6. Neptune Technologies successfully completes $2.75 million private placement with 10% management participation
7. Neptune Technologies and Marine Life Sciences enter worldwide distribution alliance with Weider Global Nutrition
8. Neptune Krill Oil, NKO(R), enters WALGREENS, the largest U.S. retail pharmacy chain, under the brand name Schiff(R) MegaRed(TM)
9. Neptune Technologies decided not to re-price options
10. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group
11. Neptune Technologies Reports Record Fiscal 2008 Fourth Quarter and Year End Results